Form 4: Design Therapeutics Director John P. Schmid Granted Stock Options

John P. Schmid, a Director at Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months.

Summary

• John P. Schmid, a Director of Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options.
• The transaction date for the option grant was June 10, 2025.
• The exercise price for these stock options is $4.01 per share.
• The options are for Common Stock, with each option representing the right to buy one share.
• The shares subject to the option will vest in equal monthly installments over 12 months following June 10, 2025.
• All shares subject to the option will be fully vested on the date of the Company's next annual meeting of stockholders, if earlier than the 12-month vesting period.
• The expiration date for these stock options is June 9, 2035.
• Following this transaction, Mr. Schmid beneficially owns 19,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns director interests with shareholders, which is generally viewed favorably. However, it is largely neutral as it represents a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director, John P. Schmid, aligns his financial interests with those of the company's shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for directors, indicating normal corporate governance practices.

Future Outlook

The granted stock options are subject to a vesting schedule, with shares vesting in equal monthly installments over 12 months following June 10, 2025, or fully vesting by the date of the Company's next annual meeting of stockholders. This indicates a future potential increase in the director's beneficial ownership of common stock as options vest and are potentially exercised.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. This practice aims to align the interests of company leadership with long-term shareholder value creation, particularly in industries with long development cycles and high R&D costs.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism across the biotech and broader public company landscape, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which also utilize equity-based incentives for their leadership.
• The vesting schedule of 12 months is a relatively common short-to-medium term vesting period for director grants, though longer periods (e.g., 3-4 years) are also prevalent for executive grants.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align the director's interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting general employees, director compensation practices can influence overall company compensation philosophy.

Next Steps

• The granted stock options will begin to vest in equal monthly installments over the 12 months following June 10, 2025.
• The options will fully vest on the date of the Company's next annual meeting of stockholders, if earlier than the 12-month period.
• John P. Schmid may choose to exercise these options at any point after they vest and before their expiration date of June 9, 2035.

Key Dates

Keywords

Design Therapeutics, DSGN, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting Schedule, Biotechnology, Pharmaceuticals